GeoVax Q2 Loss Narrows to $4.4M, But Cash Runs Out by September; New Nasdaq Delisting Risk Emerges
GOVX is trading near its 52-week low of $0.689 (10% above the low).
Summary
GeoVax reported a smaller Q2 loss of $4.4 million, but cash of $3.1 million only funds operations into September 2026. A new Nasdaq delisting rule threatens the stock, and the company's pipeline progress depends on raising more capital.
Key Events · Earnings and Guidance · GOVX
-
Q2 Loss Narrows to $4.4M
Net loss of $4.4 million vs $5.4 million a year ago, driven by a 34% cut in R&D spending after discontinuing the COVID-19 vaccine program.
-
Cash Runway Only Into September 2026
Cash and equivalents of $3.1 million as of June 30, 2026, down from $3.1 million at year-end 2025. Management states funds are sufficient only into September 2026, and the going concern warning is reiterated.
-
New Nasdaq Delisting Risk
On July 22, 2026, the SEC approved a Nasdaq rule requiring a minimum market value of listed securities of $5 million. With a market cap near $4 million, GeoVax could face immediate delisting with no cure period if it falls below the threshold for 30 consecutive trading days.
-
Strategic Shift to Mpox and Cancer Vaccines
The company discontinued its COVID-19 vaccine candidate GEO-CM04S1 and is focusing resources on GEO-MVA (mpox/smallpox) with a Phase 3 trial planned for late 2026, and Gedeptin (head and neck cancer) with a Phase 2 trial targeted for 2027.
Analysis · GOVX · Life Sciences
GeoVax's Q2 results show a narrowing loss from cost cuts, but the company has only $3.1 million in cash—enough to last just into September 2026. The going concern warning remains, and a new SEC-approved Nasdaq rule requiring a $5 million minimum market value adds immediate delisting risk given the stock's current price. The company is betting on a Phase 3 trial for its mpox vaccine and a Phase 2 for its cancer therapy, but both are capital-intensive and won't generate revenue soon. Without a financing lifeline, shareholders face severe dilution or worse.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.4% of the 440 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOVX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.69 to $20.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.